Back to Search Start Over

Concomitant use of anti-dementia drugs with psychotropic drugs in Norway-a population-based study

Authors :
Geir Selbæk
Hedvig Nordeng
Ellen Melbye Langballe
Bo Engdahl
Source :
Pharmacoepidemiology and Drug Safety. 20:1319-1326
Publication Year :
2011
Publisher :
Wiley, 2011.

Abstract

Purpose Concomitant use of anti-dementia drugs with psychotropic drugs is potentially problematic in patients with dementia. The aim of this study was to investigate how frequently patients in Norway use anti-dementia drugs concomitantly with psychotropic drugs. Methods Analyses are based on data from the Norwegian Prescription Database. All patients who had an anti-dementia drug (ATC-code N06D) dispensed from a Norwegian pharmacy between January 2004 and July 2009 were included. Results A total of 33 816 individuals received anti-dementia drugs at some time during this period. The total concomitant use of anti-dementia drugs with psychotropic drugs was 57.4% in men and 65.8% in women. Compared with men, a significantly higher percentage of women used antidepressants (35.8% versus 27.2%), mild hypnotics (28.8% versus 23.6%), benzodiazepines (25.4% versus 20.8%) and opioids (22.8% versus 17.4%) concomitantly with anti-dementia drugs. Concomitant use of antipsychotics with anti-dementia drugs was about 16% for both male and female patients. Of the total sample, 11.9% of the women and 11.7% of the men used acetylcholinesterase inhibitor (AChEI) anti-dementia drugs concomitantly with an interacting psychotropic drug. Conclusion The concomitant use of psychotropic drugs with anti-dementia drugs was extensive, especially among women. Co-medication with potentially interacting drugs occurred at a rate of one in 10. The concomitant use of anti-dementia drugs with psychotropic drugs identified in this study may inform the ongoing clinical debate about drug use in this patient group. Copyright © 2011 John Wiley & Sons, Ltd.

Details

ISSN :
10538569
Volume :
20
Database :
OpenAIRE
Journal :
Pharmacoepidemiology and Drug Safety
Accession number :
edsair.doi...........3a7e0f25c6aeb40a74d5080dc43dd812